Un Foro dirigido a inversores y fondos privados, empresas de capital riesgo y entidades del sector salud interesados en apoyar start-ups o proyectos innovadores en fase de comercialización
Read moreHealth 2.0 pretende ser el escaparate europeo ideal para explorar y examinar nuevas colaboraciones en el mundo de las TIC en salud en Europa
Read morePfizer has made an upfront payment of $87.5 million for the minority equity interest and exclusive option, with additional potential payments of up to $512.5 million upon option exercise and potential...
Read moreEn esta primera edición se destinarán 840.000 euros para la financiación de 15 proyectos, mientras que la formación que se brinda se ha valorado en otros 225.000 euros
Read moreStarting from the patented technology, the biotech has developed the Genetic Injury Report (GIR) a complete medical-genetic assessment that allows to estimate the predisposition of the professional at...
Read moreFinancing will advance Sanifit’s lead drug candidate through phase IIb as a treatment for cardiovascular diseases linked to calcification and through phase II/III for calciphylaxis
Read moreI would like for the success stories not to be counted on one hand, for investors worldwide to know Barcelona and Catalonia as a place they’re interested in doing business and for our companies to b...
Read moreLos cinco proyectos seleccionados podrán trabajar en las oficinas de Sant Joan Despí durante seis meses y recibirán 'mentoring' y 'coaching' de expertos del grupo
Read moreScientists and entrepreneurs will meet in short partnering meetings to combine their experience and projects with the aim of building a balanced team to lead successful start-up in the life sciences.
Read moreLa entrada de ProA Capital, realizada a través de una ampliación de capital, busca potenciar el crecimiento de Suanfarma, tanto de manera orgánica como mediante adquisiciones. El equipo directivo d...
Read moreYsios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners ...
Read moreArtax has validated the target and mechanism of action, and demonstrated preclinical proof of concept of AX-024 in various preclinical autoimmune disease (MS, Psoriasis, IBD, Type I diabetes) and GVHD...
Read more